TY - JOUR
T1 - Effects of transurethral resection under general anesthesia on tumor recurrence in non-muscle invasive bladder cancer
AU - Baba, Yuto
AU - Kikuchi, Eiji
AU - Shigeta, Keisuke
AU - Ogihara, Koichiro
AU - Matsushima, Masashi
AU - Nishimoto, Yui
AU - Murata, Yasuaki
AU - Asakura, Hirotaka
AU - Oyama, Masafumi
AU - Mizuno, Ryuichi
AU - Oya, Mototsugu
N1 - Funding Information:
We are grateful to Medical English Service (https://www.med-english.com/ ) for the English language review.
Publisher Copyright:
© 2021, Japan Society of Clinical Oncology.
PY - 2021/11
Y1 - 2021/11
N2 - Background: The effects of the type of anesthesia (spinal (SA) vs. general (GA)) used for transurethral resection of bladder tumor (TURBT) on non-muscle invasive bladder cancer (NMIBC) recurrence and progression are controversial and our aim is to investigate their associations. Methods: We identified 300 NMIBC patients who underwent initial TURBT with SA or GA. Cox’s regression analysis was performed to examine the effects of anesthesia on tumor recurrence. Results: Among 300 patients, 153 (51.0%) received GA and 147 (49.0%) SA. The 5-year recurrence-free survival (RFS) rate was 59.9% in the GA group, which was significantly lower than that in the SA group (74.4%, p = 0.029). GA (HR 1.57, p = 0.048), male sex (HR 2.72, p = 0.012), and tumor multiplicity (HR 1.96, p = 0.006) were independently associated with tumor recurrence. In a subgroup of 137 patients with high-risk NMIBC, the 5-year RFS rate was 50.3% in the GA group, which was significantly lower than that in the SA group (77.6%, p = 0.020), and GA remained an independent indicator of tumor recurrence (HR 2.35, p = 0.016). However, no significant differences were observed in the RFS rates of low- to intermediate-risk NMIBC patients between the GA and SA groups. Conclusions: The RFS rate was lower in NMIBC patients who received GA during TURBT than in those who received SA. Volatile anesthesia may increase tumor recurrence, particularly in high-risk NMIBC patients, which may be due to the inhibition of the immune response system during surgery.
AB - Background: The effects of the type of anesthesia (spinal (SA) vs. general (GA)) used for transurethral resection of bladder tumor (TURBT) on non-muscle invasive bladder cancer (NMIBC) recurrence and progression are controversial and our aim is to investigate their associations. Methods: We identified 300 NMIBC patients who underwent initial TURBT with SA or GA. Cox’s regression analysis was performed to examine the effects of anesthesia on tumor recurrence. Results: Among 300 patients, 153 (51.0%) received GA and 147 (49.0%) SA. The 5-year recurrence-free survival (RFS) rate was 59.9% in the GA group, which was significantly lower than that in the SA group (74.4%, p = 0.029). GA (HR 1.57, p = 0.048), male sex (HR 2.72, p = 0.012), and tumor multiplicity (HR 1.96, p = 0.006) were independently associated with tumor recurrence. In a subgroup of 137 patients with high-risk NMIBC, the 5-year RFS rate was 50.3% in the GA group, which was significantly lower than that in the SA group (77.6%, p = 0.020), and GA remained an independent indicator of tumor recurrence (HR 2.35, p = 0.016). However, no significant differences were observed in the RFS rates of low- to intermediate-risk NMIBC patients between the GA and SA groups. Conclusions: The RFS rate was lower in NMIBC patients who received GA during TURBT than in those who received SA. Volatile anesthesia may increase tumor recurrence, particularly in high-risk NMIBC patients, which may be due to the inhibition of the immune response system during surgery.
KW - General anesthesia
KW - Non-muscle invasive bladder cancer
KW - Spinal anesthesia
KW - Transurethral resection of bladder tumor
KW - Tumor recurrence
UR - http://www.scopus.com/inward/record.url?scp=85112592079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112592079&partnerID=8YFLogxK
U2 - 10.1007/s10147-021-02000-z
DO - 10.1007/s10147-021-02000-z
M3 - Article
C2 - 34357470
AN - SCOPUS:85112592079
SN - 1341-9625
VL - 26
SP - 2094
EP - 2103
JO - International Journal of Clinical Oncology
JF - International Journal of Clinical Oncology
IS - 11
ER -